Jul 21, 2022 03:25 PM

TECH

Chinese Biotech Duo Eyes $2.8 Billion Singapore Expansion

By Wen Simin and Ding Yi

Wuxi AppTec’s headquarters in Shanghai in 2019. Photo: VCG

Wuxi AppTec’s headquarters in Shanghai in 2019. Photo: VCG

Chinese contract drugmakers Wuxi AppTec Co. Ltd. and Wuxi Biologics Cayman Inc. have each unveiled a 10-year investment plan to expand their presence in Singapore — a boost to the Southeast Asian country’s effort to establish itself as a global biomedical manufacturing hub.

Wuxi Biologics was spun off from the large molecule drug subsidiary of Wuxi AppTec to list in Hong Kong in 2017. Already Shanghai-listed Wuxi AppTec landed in Hong Kong the following year.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Hopping on the Year of the Rabbit Bandwagon

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

China Stories: Strict Rules at Home Push Chinese Metaverse Entrepreneurs, Investors Overseas

00:00

00:00/00:00

MOST POPULAR

1: In Depth: China Boots Record Number of Companies From Its Bourses

2: China Shivers Through Freezing Lunar New Year as Temperature Records Tumble

3: China Urges Los Angeles Community to be Vigilant After New Year’s Day Mass Shooting

4: Bolivia Picks CATL-led Consortium to Develop Untapped Lithium Deposits

5: In Depth: What’s in Store for Yuan Internationalization in 2023?

SPONSORED

OR